Essential role of the linear ubiquitin chain assembly complex in lymphoma revealed by rare germline polymorphisms

Cancer Discovery

Volumn 4, Issue 4, 2014, Pages 480-493

  Yang, Yibin ^a   Schmitz, Roland ^a   Mitala, Joseph ^a   Whiting, Amanda ^a   Xiao, Wenming ^a   Ceribelli, Michele ^a   Wright, George W ^b   Zhao, Hong ^a   Yang, Yandan ^a   Xu, Weihong ^a   Rosenwald, Andreas ⁱ   Ott, German ^j,k   Gascoyne, Randy D ^l   Connors, Joseph M ^l   Rimsza, Lisa M ^d   Campo, Elias ^m   Jaffe, Elaine S ^a   Delabie, Jan ⁿ   Smeland, Erlend B ^n,o   Braziel, Rita M ^e   Tubbs, Raymond R ^f   Cook, James R ^f   Weisenburger, Dennis D ^g   Chan, Wing C ^h   Wiestner, Adrian ^c   Kruhlak, Michael J ^a   Iwai, Kazuhiro ^p   Bernal, Federico ^a   Staudt, Louis M ^a   more..

^a Center for Cancer Research   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^d UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f LERNER RESEARCH INSTITUTE   (United States)

^g CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^h UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF WÜRZBURG   (Germany)

^j Robert Bosch Krankenhaus   (Germany)

^k DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^l BRITISH COLUMBIA CANCER AGENCY   (Canada)

^m HOSPITAL CLÍNIC   (Spain)

ⁿ OSLO UNIVERSITY HOSPITAL   (Norway)

^o UNIVERSITY OF OSLO   (Norway)

^p KYOTO UNIVERSITY   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

IBRUTINIB; IMMUNOGLOBULIN A; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LENALIDOMIDE; RETROVIRUS VECTOR; SHORT HAIRPIN RNA; NF-KAPPA B KINASE; PEPTIDE; PROTEIN SERINE THREONINE KINASE; RBCK1 PROTEIN, HUMAN; RNF31 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; UBIQUITIN PROTEIN LIGASE;

ARTICLE; CELL VIABILITY; CELL VIABILITY ASSAY; CIRCULAR DICHROISM; CONFOCAL MICROSCOPY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FLUORESCENCE POLARIZATION; GERM LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOPRECIPITATION; LARGE CELL LYMPHOMA; LYMPHOMA; MAJOR CLINICAL STUDY; PEPTIDE SYNTHESIS; POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; TOXICITY; TUMOR BIOPSY; UBIQUITINATION; WESTERN BLOTTING; BINDING SITE; CHEMICAL STRUCTURE; GENETIC VARIABILITY; GENETICS; GERMLINE MUTATION; METABOLISM; PATHOLOGY; PROTEIN SECONDARY STRUCTURE; SYNTHESIS; TUMOR CELL LINE;

BINDING SITES; CELL LINE, TUMOR; CIRCULAR DICHROISM; GENETIC VARIATION; GERM-LINE MUTATION; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MODELS, MOLECULAR; PEPTIDES; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN STRUCTURE, SECONDARY; PROTEIN-SERINE-THREONINE KINASES; TRANSCRIPTION FACTORS; UBIQUITIN-PROTEIN LIGASES;

EID: 84897942317     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-13-0915     Document Type: Article

References (50)

1. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503-11.
2. Shaffer AL III, Young RM, Staudt LM. Pathogenesis of human B cell lymphomas. Annu Rev Immunol 2012; 30: 565-610.
3. Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive nuclear factor kappa B activity is required for survival of activated B Cell-like diffuse large B cell lymphoma cells. J Exp Med 2001; 194: 1861-74.
4. Yang Y, Shaffer AL III, Emre NC, Ceribelli M, Zhang M, Wright G, et al. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell 2012; 21: 723-37.
5. Ngo VN, Davis RE, Lamy L, Yu X, Zhao H, Lenz G, et al. A loss-offunction RNA interference screen for molecular targets in cancer. Nature 2006; 441: 106-10.
6. Lenz G, Davis RE, Ngo VN, Lam L, George TC, Wright GW, et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 2008; 319: 1676-9.
7. Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010; 463: 88-92.
8. Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim KH, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 2011; 470: 115-9.
9. Lam LT, Wright G, Davis RE, Lenz G, Farinha P, Dang L, et al. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma. Blood 2008; 111: 3701-13.
10. Chen ZJ. Ubiquitination in signaling to and activation of IKK. Immunol Rev 2012; 246: 95-106.
11. Tokunaga F, Sakata S, Saeki Y, Satomi Y, Kirisako T, Kamei K, et al. Involvement of linear polyubiquitylation of NEMO in NF-kappaB activation. Nat Cell Biol 2009; 11: 123-32.
12. Ikeda F, Deribe YL, Skanland SS, Stieglitz B, Grabbe C, Franz-Wachtel M, et al. SHARPIN forms a linear ubiquitin ligase complex regulating NF-kappaB activity and apoptosis. Nature 2011; 471: 637-41.
13. Tokunaga F, Nakagawa T, Nakahara M, Saeki Y, Taniguchi M, Sakata S, et al. SHARPIN is a component of the NF-kappaB-activating linear ubiquitin chain assembly complex. Nature 2011; 471: 633-6.
14. Gerlach B, Cordier SM, Schmukle AC, Emmerich CH, Rieser E, Haas TL, et al. Linear ubiquitination prevents infl ammation and regulates immune signalling. Nature 2011; 471: 591-6.
15. Haas TL, Emmerich CH, Gerlach B, Schmukle AC, Cordier SM, Rieser E, et al. Recruitment of the linear ubiquitin chain assembly complex stabilizes the TNF-R1 signaling complex and is required for TNFmediated gene induction. Mol Cell 2009; 36: 831-44.
16. Hostager BS, Fox DK, Whitten D, Wilkerson CG, Eipper BA, Francone VP, et al. HOIL-1L interacting protein (HOIP) as an NF-kappaB regulating component of the CD40 signaling complex. PLoS ONE 2010; 5: e11380.
17. Hostager BS, Kashiwada M, Colgan JD, Rothman PB. HOIL-1L interacting protein (HOIP) is essential for CD40 signaling. PLoS ONE 2011; 6: e23061.
18. Zak DE, Schmitz F, Gold ES, Diercks AH, Peschon JJ, Valvo JS, et al. Systems analysis identifies an essential role for SHANK-associated RH domain-interacting protein (SHARPIN) in macrophage Toll-like receptor 2 (TLR2) responses. Proc Natl Acad Sci U S A 2011; 108: 11536-41.
19. Sasaki Y, Sano S, Nakahara M, Murata S, Kometani K, Aiba Y, et al. Defective immune responses in mice lacking LUBAC-mediated linear ubiquitination in B cells. EMBO J 2013; 32: 2463-76.
20. Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008; 359: 2313-23.
21. 1000 Genomes Project Consortium, Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, et al. An integrated map of genetic variation from 1,092 human genomes. Nature 2012; 491: 56-65.
22. Tennessen JA, Bigham AW, O'Connor TD, Fu W, Kenny EE, Gravel S, et al. Evolution and functional impact of rare coding variation from deep sequencing of human exomes. Science 2012; 337: 64-9.
23. Yagi H, Ishimoto K, Hiromoto T, Fujita H, Mizushima T, Uekusa Y, et al. A non-canonical UBA-UBL interaction forms the linear-ubiquitin- chain assembly complex. EMBO Rep 2012; 13: 462-8.
24. Lam LT, Davis RE, Pierce J, Hepperle M, Xu Y, Hottelet M, et al. Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clin Cancer Res 2005; 11: 28-40.
25. Hailfinger S, Lenz G, Ngo V, Posvitz-Fejfar A, Rebeaud F, Guzzardi M, et al. Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A 2009; 106: 19946-51.
26. Ferch U, Kloo B, Gewies A, Pfander V, Duwel M, Peschel C, et al. Inhibition of MALT1 protease activity is selectively toxic for activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2009; 206: 2313-20.
27. Tokunaga F, Nishimasu H, Ishitani R, Goto E, Noguchi T, Mio K, et al. Specific recognition of linear polyubiquitin by A20 zinc finger 7 is involved in NF-kappaB regulation. EMBO J 2012; 31: 3856-70.
28. Verhelst K, Carpentier I, Kreike M, Meloni L, Verstrepen L, Kensche T, et al. A20 inhibits LUBAC-mediated NF-kappaB activation by binding linear polyubiquitin chains via its zinc finger 7. EMBO J 2012; 31: 3845-55.
29. Smit JJ, Monteferrario D, Noordermeer SM, van Dijk WJ, van der Reijden BA, Sixma TK. The E3 ligase HOIP specifies linear ubiquitin chain assembly through its RING-IBR-RING domain and the unique LDD extension. EMBO J 2012; 31: 3833-44.
30. Stieglitz B, Morris-Davies AC, Koliopoulos MG, Christodoulou E, Rittinger K. LUBAC synthesizes linear ubiquitin chains via a thioester intermediate. EMBO Rep 2012; 13: 840-6.
31. Walensky LD, Kung AL, Escher I, Malia TJ, Barbuto S, Wright RD, et al. Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science 2004; 305: 1466-70.
32. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest 2001; 107: 241-6.
33. McCool KW, Miyamoto S. DNA damage-dependent NF-kappaB activation: NEMO turns nuclear signaling inside out. Immunol Rev 2012; 246: 311-26.
34. Niu J, Shi Y, Iwai K, Wu ZH. LUBAC regulates NF-kappaB activation upon genotoxic stress by promoting linear ubiquitination of NEMO. EMBO J 2011; 30: 3741-53.
35. Barlow DJ, Thornton JM. Helix geometry in proteins. J Mol Biol 1988; 201: 601-19.
36. Oeckinghaus A, Wegener E, Welteke V, Ferch U, Arslan SC, Ruland J, et al. Malt1 ubiquitination triggers NF-kappaB signaling upon T-cell activation. EMBO J 2007; 26: 4634-45.
37. Sun L, Deng L, Ea CK, Xia ZP, Chen ZJ. The TRAF6 ubiquitin ligase and TAK1 kinase mediate IKK activation by BCL10 and MALT1 in T lymphocytes. Mol Cell 2004; 14: 289-301.
38. Pelzer C, Cabalzar K, Wolf A, Gonzalez M, Lenz G, Thome M. The protease activity of the paracaspase MALT1 is controlled by monoubiquitination. Nat Immunol 2013; 14: 337-45.
39. Boisson B, Laplantine E, Prando C, Giliani S, Israelsson E, Xu Z, et al. Immunodeficiency, autoinfl ammation and amylopectinosis in humans with inherited HOIL-1 and LUBAC deficiency. Nat Immunol 2012; 13: 1178-86.
40. Green NM, Marshak-Rothstein A. Toll-like receptor driven B cell activation in the induction of systemic autoimmunity. Semin Immunol 2011; 23: 106-12.
41. Janoueix-Lerosey I, Lequin D, Brugieres L, Ribeiro A, de Pontual L, Combaret V, et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 2008; 455: 967-70.
42. Mosse YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008; 455: 930-5.
43. Yokoyama S, Woods SL, Boyle GM, Aoude LG, MacGregor S, Zismann V, et al. A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature 2011; 480: 99-103.
44. Bertolotto C, Lesueur F, Giuliano S, Strub T, de Lichy M, Bille K, et al. A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature 2011; 480: 94-8.
45. Abe M, Nozawa Y, Wakasa H, Ohno H, Fukuhara S. Characterization and comparison of two newly established Epstein-Barr virus-negative lymphoma B-cell lines. Surface markers, growth characteristics, cytogenetics, and transplantability. Cancer 1988; 61: 483-90.
46. Tweeddale ME, Lim B, Jamal N, Robinson J, Zalcberg J, Lockwood G, et al. The presence of clonogenic cells in high-grade malignant lymphoma: a prognostic factor. Blood 1987; 69: 1307-14.
47. Tohda S, Sato T, Kogoshi H, Fu L, Sakano S, Nara N. Establishment of a novel B-cell lymphoma cell line with suppressed growth by gamma-secretase inhibitors. Leuk Res 2006; 30: 1385-90.
48. Maesako Y, Uchiyama T, Ohno H. Comparison of gene expression profiles of lymphoma cell lines from transformed follicular lymphoma, Burkitt's lymphoma and de novo diffuse large B-cell lymphoma. Cancer Sci 2003; 94: 774-81.
49. Schmitz R, Young RM, Ceribelli M, Jhavar S, Xiao W, Zhang M, et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 2012; 490: 116-20.
50. Bernal F, Tyler AF, Korsmeyer SJ, Walensky LD, Verdine GL. Reactivation of the p53 tumor suppressor pathway by a stapled p53 peptide. J Am Chem Soc 2007; 129: 2456-7.